2. Search Result
Search Result
Results for "

gallbladder

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

5

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W587430
    Glycolithocholic acid 3-sulfate disodium

    Glycolithocholate sulfate disodium; Sulfolithocholylglycine disodium; SLCG disodium

    		 HIV Infection
    Glycolithocholic acid 3-sulfate (disodium) inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate (disodium) can be used for the research of HIV infection and gallbladder disease .
    Glycolithocholic acid 3-sulfate disodium
  • HY-113074
    Glycolithocholic acid 3-sulfate

    Glycolithocholate sulfate; Sulfolithocholylglycine; SLCG

    		 HIV Endogenous Metabolite Infection Inflammation/Immunology
    Glycolithocholic acid 3-sulfate (SLCG) is a cholic acid derivative and a metabolite of glycolithocholic acid. Glycolithocholic acid 3-sulfate inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate can be used for the research of HIV infection and gallbladder disease .
    Glycolithocholic acid 3-sulfate
  • HY-P0093
    Sincalide
    3 Publications Verification

    Cholecystokinin octapeptide; CCK-8; SQ19844
    Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide
  • HY-P0093A
    Sincalide ammonium
    3 Publications Verification

    Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

    		 Cholecystokinin Receptor Apoptosis PI3K Akt Infection Cancer
    Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide ammonium
  • HY-146453
    TGR5 Receptor Agonist 3

    		G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    TGR5 Receptor Agonist 3 (Compound 19) is a soft-agent G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist with reduced gallbladder-filling effects (favorable gallbladder safety), with EC50s of 16.4 and 209 nM for hTGR5 and mTGR5, respectively.
    TGR5 Receptor Agonist 3
  • HY-A0190
    Ceruletide
    Maximum Cited Publications
    67 Publications Verification

    Caerulein; Cerulein; FI-6934

    		 Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Ceruletide
  • HY-106301
    Devazepide
    1 Publications Verification

    L-364,718; MK-329

    		 Cholecystokinin Receptor Metabolic Disease
    Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .
    Devazepide
  • HY-118546
    JNJ-17156516

    		Cholecystokinin Receptor Inflammation/Immunology
    JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist .
    JNJ-17156516
  • HY-136453
    CR-1-31-B
    5 Publications Verification

    		 Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells .
    CR-1-31-B
  • HY-101764
    Lintitript

    SR 27897

    		 Cholecystokinin Receptor Metabolic Disease
    Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
    Lintitript

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: